Crossmark

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

Crossref DOI link: https://doi.org/10.1186/s12885-018-4283-z

Published Online: 2018-05-25

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Markóczy, Zsolt

Sárosi, Veronika

Kudaba, Iveta

Gálffy, Gabriella

Turay, Ülkü Yilmaz

Demirkazik, Ahmet

Purkalne, Gunta

Somfay, Attila

Pápai-Székely, Zsolt

Rásó, Erzsébet

Ostoros, Gyula https://orcid.org/0000-0001-5339-7257
Funding

Funding for this research was provided by:

Hoffmann-La Roche Ltd, Basel, Switzerland
License Information

Text and Data Mining valid from 2018-05-25
More Information

Article History

Received: 2 August 2017

Accepted: 21 March 2018

First Online: 25 May 2018

Consent for publication

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below